# Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831

> **NCT04480333** · PHASE1 · UNKNOWN · sponsor: **Biomed Industries, Inc.** · enrollment: 45 (estimated)

## Conditions studied

- Covid19
- Corona Virus Infection
- Severe Acute Respiratory Syndrome
- Severe Acute Respiratory Infection
- Severe Acute Respiratory Syndrome (SARS) Pneumonia
- Severe Acute Respiratory Syndrome of Upper Respiratory Tract
- Neurodegeneration
- Neuroinflammatory Response

## Interventions

- **DRUG:** Drug: NA-831 - 0.10 mg/kg
- **DRUG:** Placebo- 0.10 mg/kg
- **DRUG:** Drug: NA-831 - 0.20 mg/kg
- **DRUG:** Placebo- 0.20 mg/kg
- **DRUG:** Drug: GS-5734 - 1.00 mg/kg
- **DRUG:** Placebo- 1.00 mg/kg
- **DRUG:** Drug: GS-5734 - 2.00 mg/kg
- **DRUG:** Placebo- 2.00 mg/kg
- **COMBINATION_PRODUCT:** Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg)
- **COMBINATION_PRODUCT:** Placebo 0.10 mg + 1.00 mg/kg
- **COMBINATION_PRODUCT:** Drugs: NA-831 (0.20 mg/kg) plus GS-5734 (2.00 mg/kg)
- **COMBINATION_PRODUCT:** Placebo 0.20 mg + 2.00 mg/kg

## Key facts

- **NCT ID:** NCT04480333
- **Lead sponsor:** Biomed Industries, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09-15
- **Primary completion:** 2020-12-31
- **Final completion:** 2021-03-31
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2020-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04480333

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04480333, "Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04480333. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*